Home Cart 0 Sign in  

[ CAS No. 1022150-11-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 1022150-11-3
Chemical Structure| 1022150-11-3
Structure of 1022150-11-3 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1022150-11-3 ]

Related Doc. of [ 1022150-11-3 ]

Alternatived Products of [ 1022150-11-3 ]

Product Details of [ 1022150-11-3 ]

CAS No. :1022150-11-3 MDL No. :MFCD28167899
Formula : C27H30N6O3 Boiling Point : -
Linear Structure Formula :- InChI Key :NTSAEGNFPKKRLX-LJQANCHMSA-N
M.W : 486.57 Pubchem ID :59799012
Synonyms :

Safety of [ 1022150-11-3 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1022150-11-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1022150-11-3 ]
  • Downstream synthetic route of [ 1022150-11-3 ]

[ 1022150-11-3 ] Synthesis Path-Upstream   1~26

  • 1
  • [ 1276110-38-3 ]
  • [ 51067-38-0 ]
  • [ 1022150-11-3 ]
YieldReaction ConditionsOperation in experiment
64% With sodium carbonate In 1,4-dioxane; water at 90℃; for 24 h; Inert atmosphere Step 4A mixture of (R)-tert-butyl 3-[4-amino-3-iodo-lH-pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l-carboxylate (1 g, 2.25 mmol, 1 .00 equiv), (4-phenoxyphenyl)boronic acid (530 mg, 2.48 mmol, 1.10 equiv), sodium carbonate (480 mg, 4.53 mmol, 2.01 equiv) and tetrakis( triphenylphosphine)palladium (78 mg, 0.07 mmol, 0.03 equiv) in ,4-dioxane (60 mL) and water (15 mL) was stirred under nitrogen at 90°C for 24 h. The reaction mixture was cooled to room temperature and then concentrated under vacuum. The residue was dissolved in 500 mL of dichloromethane. The resulting solution was washed with 200 mL of water, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified on a silica gel column eluted with dichloromethane/methanol (100/1) to give 700 mg (64percent) of (R)-tert-butyl 3-[4-amino-3-(4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l-carboxylate as a yellow solid.
64% With tetrakis(triphenylphosphine) palladium(0); sodium carbonate In 1,4-dioxane; water at 90℃; for 24 h; Inert atmosphere A mixture of (R)-tert-butyl 3[4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate (1 g, 2.2.5 mmol, 1.00 equiv), (4-phenoxyphenyl)boronic acid (530 mg, 2.48 mmol, 1.10 equiv), sodium carbonate (480 mg, 4.53 mmol, 2.01 equiv) and tetrakis(triphenyiphosphine)palladium (78 mg, 0.07 mmol, 0.03 equiv) in 1,4-dioxane (60 mL) and water (15 mL) was stirred under nitrogen at 90°C for 24 h. The reaction mixture was cooled to room temperature and then concentrated under vacuum. The residue was dissolved in 500 mL of dichloromethane. The resulting solution was washed with 200 mL of water, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified on a silica gel column eluted with dichloromethauefmethanol (100/1) to give 700 mg (64percent) of (R)ert-butyl 1H-pyrazolo[3,4-d]pyrimidin-1-yi]piperidine-1-carboxylate as a yellow solid.
64% With tetrakis(triphenylphosphine) palladium(0); sodium carbonate In 1,4-dioxane; water at 90℃; for 24 h; Inert atmosphere Step 4. A mixture of tert-butyl 3-[4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate (1 g, 2.25 mmol, 1.00 equiv), (4-phenoxyphenyl)boronic acid (530 mg, 2.48 mmol, 1.10 equiv), sodium carbonate (480 mg, 4.53 mmol, 2.01 equiv) and tetrakis(triphenylphosphine)palladium (78 mg, 0.07 mmol, 0.03 equiv) in 1,4-dioxane (60 mL) and water (15 mL) was stirred under nitrogen at 90°C for 24 h. The reaction mixture was cooled to room temperature and then concentrated under vacuum. The residue was dissolved in 500 mL of dichloromethane. The resulting solution was washed with 200 mL of water, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified on a silica gel column eluted with dichloromethane/methanol (100/1) to give 700 mg (64percent) of tert-butyl 3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate as a yellow solid.
64% With tetrakis(triphenylphosphine) palladium(0); sodium carbonate In 1,4-dioxane; water at 90℃; for 24 h; Inert atmosphere Step 4
A mixture of tert-butyl 3-[4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate (1 g, 2.25 mmol, 1.00 equiv), (4-phenoxyphenyl)boronic acid (530 mg, 2.48 mmol, 1.10 equiv), sodium carbonate (480 mg, 4.53 mmol, 2.01 equiv) and tetrakis(triphenylphosphine)palladium (78 mg, 0.07 mmol, 0.03 equiv) in 1,4-dioxane (60 mL) and water (15 mL) was stirred under nitrogen at 90° C. for 24 h.
The reaction mixture was cooled to room temperature and then concentrated under vacuum.
The residue was dissolved in 500 mL of dichloromethane.
The resulting solution was washed with 200 mL of water, dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was purified on a silica gel column eluted with dichloromethane/methanol (100/1) to give 700 mg (64percent) of tert-butyl 3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate as a yellow solid.
60% With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; sodium carbonate In 1,4-dioxane; water at 80℃; Inert atmosphere (R) -1-Boc-3- (4-amino-3-iodo-1H-pyrazolo [3,4-D] pyrimidin-1-yl) piperidine (12.8G, 29 mmol),4-phenoxyphenylboronic acid (6.8 g, 32 mmol),PdCl2 (dppf) (0.5 g, 0.69 mmol),Sodium carbonate (6.1 g, 58 mmol),1,4-dioxane (160 ml) and water (40 ml) were added and the mixture was heated to 80 ° C overnight.After confirming the completion of the reaction,Filter, spin dry,Add water, extract with ethyl acetate, dry,The product was purified by column chromatography (8.5 g, yield 60percent).

Reference: [1] Patent: WO2012/158795, 2012, A1, . Location in patent: Page/Page column 76
[2] Patent: WO2013/191965, 2013, A1, . Location in patent: Page/Page column 156
[3] Patent: WO2014/22569, 2014, A1, . Location in patent: Page/Page column 50
[4] Patent: US8673925, 2014, B1, . Location in patent: Page/Page column 201
[5] Patent: CN106146511, 2016, A, . Location in patent: Paragraph 0150; 0151; 0152
[6] Patent: WO2016/151438, 2016, A1, . Location in patent: Page/Page column 12-13
  • 2
  • [ 330786-24-8 ]
  • [ 143900-44-1 ]
  • [ 1022150-11-3 ]
YieldReaction ConditionsOperation in experiment
88.1% With di-isopropyl azodicarboxylate; triphenylphosphine In ethyl acetate at 10 - 30℃; Darkness; Industrial scale 600g of (S) -t-butyloxycarbonyl-3-hydroxypiperidine, 780g of triphenylphosphine and 3L of ethyl acetate was added to the reaction flask and stirred to be clear,After clearing, 300 g of 4-amino-3- (4-phenoxyphenyl) -1H-pyrido (3,4-d)Continue stirring 10 ~ 30min,Dark, temperature control at 10 ~ 15 ° C began to drop under the conditions of diisopropyl azodicarboxylate,After the addition was completed, the temperature was raised to 25 ~ 30 ° C, the reaction was stirred 3 ~ 4h; stop the reaction, cooled to 0 ° C,Start dropping lllOmL concentrated HC1, after the addition was completed, warmed to room temperature, the reaction was stirred 3 ~ 4h; stop the reaction,Add 3L of purified water and stir, then respectively add 1.8L chloroform extraction 5 times and 1.8L ethyl acetate extraction 2 times,After extraction, add 1.2L of ethyl acetate, cooled to 0 ° C, began dropping 25percent NaOH solution,Adjust the pH value to 8 ~ 9, precipitated a large amount of solid, stirring crystallization, crystallization end, centrifugal rejection rejection,The filter cake was washed with a small amount of ethyl acetate, the resulting filter cake 55 ~ 60 ° C under vacuum,Vacuum -0.080MPa ~-0 lOOMPa,Intermediate I336.3g, yield 88.1percent.
72%
Stage #1: With di-isopropyl azodicarboxylate; triphenylphosphine In tetrahydrofuran at 0 - 5℃; for 0.166667 h; Inert atmosphere
Stage #2: at 0 - 20℃; for 5 h; Inert atmosphere
Under nitrogen protection, Ph3P (29.0 g, 112 mmol, 1.25 eq), (3S)-hydroxy-1-tert-butoxycarbonylpiperidine (18.0 g, 89.3 mmol, 1.0 eq) dissolved in tetrahydrofuran 150ml, cooled to 0 °C , the control temperature does not exceed 5 °C , in 20-30 min by adding DIAD (25.1g, 125mmol, 1.4eq) in tetrahydrofuran (40ml) solution, add, the yellow solution to continue stirring 10min.And then added at 0~5 °C 4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine (28.1 g, 93.9 mmol, 1.05 eq)In tetrahydrofuran (150 ml) was added and the mixture was stirred at room temperature for 5h. Add water 3.2ml, warm to 50-60 °C 30min, Then, magnesium chloride (27.0 g, 280 mmol, 2.5 eq) was added, stirred at reflux for 2.5 h, Cooled to 0 ° C, filtered, washed with tetrahydrofuran (50 ml x 2), removed by rotary evaporation to remove the solvent, The residual oily substance was beaten with ethyl acetate (300 ml), n-hexane (50 ml) was added, filtered, and the residue was washed with ethyl acetate (30 ml x 2). The filtrate was washed with water (100 ml x 2), saturated brine (150 ml) Washed with anhydrous sodium sulfate, the filtrate was removed by rotary evaporation solvent, the residue Ph3PO content: 5.6wtpercent, and then adding isopropyl alcohol (40ml) in the residue to 50-60 ° C stirring, cooling crystallization, Filtration of a small amount of cold isopropanol and drying in vacuo gave 28.1 g of product (yield 72percent by weight, pale yellow solid), Ph3PO content: 0.8 wtpercent.
69% With di-isopropyl azodicarboxylate; triphenylphosphine In tetrahydrofuran at 20℃; for 1.05 - 1.08333 h; Heating / reflux To a solution of 1-boc-3-(S)-hydroxypiperidine (3.98 g, 19.8 mmol) and triphenylphosphine (5.19 g, 19.8 mmol) in THF (150 ml) was added DIAD (3.9 ml, 19.8 mmol). The yellow solution was stirred 1 minute then Intermediate 2 (4.0 g, 13.2 mmol) was added and the reaction was heated with a heat gun (3-5 minutes) until the solid had dissolved. After stirring for 1 hour at room temperature, the solvent was removed and the resulting brown oil was subjected to flash chromatography (30percent then 50percent THF/hexanes) to provide 4.45 g (69percent) of Intermediate 3 (trace of triphenylphosphine oxide is present) as a light brown foam.
38% With di-isopropyl azodicarboxylate; triphenylphosphine In tetrahydrofuran at 20℃; Example 1. Synthesis of (i?)-l-('3-(4-Amino-3-('4-phenoxyphenyl)-lH- pyrazolo [3 A-d] pyrimidin- 1 -yQpiperidin- 1 -yl)prop-2-en-2,3 ,3 -dy 1 -one (Compound 122). Scheme 5. Preparation of Compound 122 35 36 Compound 122 [96] Step 1. 3-Iodo-lH-pyrazolo[3,4-^pyrimidin-4-amine (31). lH-Pyrazolo[3,4- d]pyrimidin-4-amine, 30 (5.0 g, 37 mmol, 1 equiv) was suspended in DMF (100 mL) and N-iodosuccinimide ( IS) (10.7 g, 45 mmol, 1.2 equiv) was added. The reaction was heated at 80 °C for 2 hours. The reaction was cooled to room temperature and then to 0 °C and was quenched by the drop-wise addition of water (200 mL). The resulting solids were collected by filtration, washed with water and cold ethanol, and dried in a vacuum oven to yield 31 (8.1 g, 84percent yield) as a beige solid. [97] Step 2. Phenoxyphenyl -lH-pyrazolo[3,4-< ]pyrimidin-4-amine (33). Compound 31 (4.0 g, 15.3 mmol, 1 equiv), boronic acid 32 (6.56 g, 30.7 mmol, 2 equiv), and potassium phosphate tribasic monohydrate (10.56 g, 45.9 mmol, 3 equiv) were dissolved in dioxane (50 mL) and water (20 mL). The mixture was sparged with nitrogen for 20 minutes and tetrakis(triphenylphosphine)palladium (2.70 g, 2.3 mmol, 0.15 equiv) was added. The mixture was sparged with nitrogen for an additional 5 minutes and then heated at reflux for 24 hours. The reaction was cooled to room temperature and stirred overnight, giving a beige precipitate. The reaction mixture was diluted with water (50 mL) and the solids were collected by filtration. The crude product was triturated with methanol (150 mL) to yield 3.9 g of 85percent pure product. The purity was further improved by trituration with ethyl acetate (100 mL), yielding 33 (3.6 g, 77percent yield, 90percent pure) as a beige solid. [98] Step 3. (R ert-Butyl 3-(4-amino-3-(4-phenoxyphenvn-lH-pyrazoror3.4- Compound 33 (1.80 g, 5.9 mmol, 1 equiv), protected piperidine, 34 (1.43 g, 7.1 mmol, 1.2 equiv), triphenylphosphine (2.33 g, 8.9 mmol, 1.5 equiv), and diisopropyl azodicarboxylate (1.80 g, 8.9 mmol, 1.5 equiv) were dissolved in THF (200 mL) and stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate (200 mL) and washed with saturated aqueous sodium bicarbonate (1 x 300 mL) and brine (1 x 300 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude material was adsorbed onto silica gel and purified using an Analogix automated chromatography system eluting with 0-8percent methanol in dichloromethane. All fractions containing product were combined and re- chromatographed using the above conditions to yield 35 (1.1 g, 38percent yield) as a white foam. [99] Step 4. (7?V3-(4-Phenoxyphenvn- 1 -(piperidin-3-νΠ- 1 //-pyrazoloH A- dlpyrimidin-4-amine hydrochloride (36). Compound 35 (700 mg, 1.48 mmol, 1 equiv) was dissolved in dioxane (8 mL). A solution of hydrogen chloride in dioxane (4 mL of a 4 N solution in dioxane, 16 mmol, 10.7 equiv) was added and the reaction was stirred at room temperature overnight. The reaction was diluted with diethyl ether (20 mL) and the resulting solids were collected by filtration under a stream of nitrogen. The product was further dried in a vacuum oven to yield 36 (550 mg, 88percent yield) as an off-white solid. [100] Step 5. (_)- l-(3-(4-Amino-3-(4-phenoxyphenyl)- lH-pyrazolor3,4- ( Ipyrimidin- 1 -yDpiperidin- 1 -yl)prop-2-en-2,3 ,3 -dy- 1 -one (Compound 122). [101] A) DMF (0.003 mL, 0.03 mmol, 0.02 equiv) was added to commercially available acrylic acid-d4 (126 mg, 1.66 mmol, 1 equiv, 99 atom percent D) followed by oxalyl chloride (0.16 mL, 1.83 mmol, 1.1 equiv). The mixture was stirred for 30 minutes, at which point all gas evolution had ceased. The resulting acryloyl-d3 chloride (37) was used as such. [102] B) In a 20 mL vial, triethylamine (0.46 mL, 3.18 mmol, 3 equiv) was added to a suspension of 36 (450 mg, 1.06 mmol, 1 equiv) in dichloromethane (10 mL). The reaction was stirred for 15 minutes, resulting in a clear solution. Acryloyl-d3 chloride (37) (0.10 mL, 1.17 mmol, 1.1 equiv, prepared above) was then added and the reaction was stirred at room temperature for 2 hours. The reaction mixture was diluted with dichloromethane (50 mL) and washed with 5percent citric acid (50 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude material was purified using an Analogix automated chromatography system eluting with 0-8percent methanol in dichloromethane. All fractions containing product were pooled and concentrated to give a colorless film which was dissolved in benzene/methanol (5 mL) and lyophilized to yield Compound 122 (170 mg, 36percent yield, [M+H]+ = 444.3) as a white powder.
0.3 g
Stage #1: With di-isopropyl azodicarboxylate; triphenylphosphine In tetrahydrofuran
Stage #2: at 20℃;
Diisopropyl diazodicarboxylate (DAID, 1.2 ml) was added to a solution of 1-tert-butyloxycarbonyl-3-(S)-hydroxypiperidine ( 1.0 g,) and triphenylphosphine (2.59g) in tetrahydrofuran (50.0ml). To the resulting yellow solution, 3-(p-phenoxyphenyl)-1,2,5,7-tetraza-1H-inden-4-ylamine (1.0g). was added and warmed till dissolution, and stirred overnight at room temperature. The reaction mixture was filtered and the solvent was distilled under vacuum to get an oily residue, which was further purified by flash chromatography (30-50 percent ethyl acetate/ hexane) on silicagel to give 0.3 g (0.3 w/w) of tert-butyloxycarbonyl-(1S)-1-[(3R)-3-piperidyl]-3-(p-phenoxyphenyl)-1,2,5,7-tetraza-1H-inden-4-ylamine as a light brown solid. The resulting solid was dissolved in dichloromethane (5 ml) and trifluoroacetic acid (0.6 ml) was added to it. After completion of reaction, water was added to reaction mass, followed by addition of methyl tert-butyl ether (20.0 ml). The layers were separated and the aqueous layer was basified with potassium carbonate and extracted with dichloromethane (15.0 ml x 2). The organic layer dried over sodium sulfate, filtered and evaporated to yield 0.2 g (0.6 w/w) of title compound as light yellow oil.

Reference: [1] Patent: CN106995446, 2017, A, . Location in patent: Paragraph 0044-0046
[2] Patent: CN106967071, 2017, A, . Location in patent: Paragraph 0019
[3] Patent: US2008/214501, 2008, A1, . Location in patent: Page/Page column 12
[4] Organic and Biomolecular Chemistry, 2015, vol. 13, # 18, p. 5147 - 5157
[5] Patent: WO2014/22390, 2014, A1, . Location in patent: Paragraph 95; 98
[6] Journal of Medicinal Chemistry, 2015, vol. 58, # 24, p. 9625 - 9638
[7] Patent: CN105481862, 2016, A, . Location in patent: Paragraph 0166; 0167; 0170
[8] Patent: WO2017/163257, 2017, A1, . Location in patent: Page/Page column 19
[9] Patent: CN106008526, 2016, A, . Location in patent: Paragraph 0016; 0063; 0064; 0065
[10] Patent: CN107759602, 2018, A, . Location in patent: Paragraph 0231; 0236-0237
  • 3
  • [ 940890-90-4 ]
  • [ 330786-24-8 ]
  • [ 1022150-11-3 ]
YieldReaction ConditionsOperation in experiment
80%
Stage #1: With potassium carbonate In N,N-dimethyl-formamide at 21 - 22℃; for 2 h;
Stage #2: at 80℃; for 14 h;
Intermediate 1 (5g) was dissolved in dry DMF (50 mL) and potassium carbonate (8.8 g) was added. The suspension was stirred at ambient temperature for 2 h. After dropwise addition of Intermediate 2 (9 g) dissolved in DMF (10 mL) the reaction mixture was heated at 80°C for 14 h. The organic layer was separated and the water layer extracted with EtOAc (3x20 mL). The organic layers were combined and dried over Na2SC>4. Solvent evaporation at reduced pressure and recrystallization result in 6.3g (80percent) tert-butyl-(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo [3,4-d] pyrimidin- 1 -yl]piperidine - 1 -carboxylate.
70% With dmap; caesium carbonate In N,N-dimethyl-formamide at 90℃; for 8 h; 3-(4-phenoxyphenyl) lH-pyrazolo [3,4-d] pyrimidin-4-amine (1.14g, 3.76mmol)was dissolved DMF (30mL) in, and then the reaction solution was added (S)-tert-butyl 3-((methylsulfonyl) oxy) piperidine-1-carboxylate (4.2g, 15.04mmol), cesium carbonate(0.64mL, 8.21 mmol), 4- dimethylaminopyridine pyridine (3.67g, 11.28mmol). Was stirredat 90 deg.] C 8h, the reaction was completed, distilled under reduced pressure of DMF,and extracted with dichloromethane (150mL × 3), brine (60mL), dried over anhydroussodium sulfate, the solvent was distilled off under reduced pressure, the crude productwas silica gel column Analysis of separation and purification (methylene chloride /methanol (V / V) = 40/1), to give the product (1.28g, 70percent).
Reference: [1] Patent: WO2017/137446, 2017, A1, . Location in patent: Page/Page column 15; 18; 19
[2] Patent: CN105399756, 2016, A, . Location in patent: Paragraph 0155; 0173-0174
  • 4
  • [ 330786-24-8 ]
  • [ 1022150-11-3 ]
YieldReaction ConditionsOperation in experiment
82% With caesium carbonate In N,N-dimethyl-formamide at 100℃; for 12 h; Compound 2g (6.6mmol) of Formula 8 and 1.4g (6.6mmol) t-butyl -3S- chloro - piperidine-1-AEster, 4.6g of cesium carbonate was dissolved 30mlDMF, heated to 100 , for 12 hours. The reaction mixture was pouredInto 150ml water and extracted with ethyl acetate, the organic phase was dried and concentrated to give a pale yellow solid 2.63g,Yield 82percent.
Reference: [1] Patent: CN105622613, 2016, A, . Location in patent: Paragraph 0109; 0198; 0199; 0200; 0201; 0202; 0203
  • 5
  • [ 101-55-3 ]
  • [ 1022150-11-3 ]
YieldReaction ConditionsOperation in experiment
66% With 1,10-Phenanthroline; palladium diacetate; potassium carbonate In N,N-dimethyl acetamide at 150℃; for 16 h; Sealed tube; Inert atmosphere A mixture of compound (III) (Pgi = Boc, Pg2 = H) (636 mg, 2.00 mmol), Pd(OAc)2 (44 mg,0.20 mmol), 1,10-phenanthroline (36 mg, 0.20 mmol), K2C03 (304 mg, 2.20 mmol), 1-bromo-4-phenoxybenzene (548 mg, 2.20 mmol) and N,N-dimethylacetamide (DMA) (10 ml)was heated in a sealed tube under argon atmosphere at 150°C for 16 h with intensive stirring.The product (III) was isolated and purified similarly to that described in the Example 1. Yield642 mg (66percent), viscous yellowish oil. The analytical data of the obtained compound (III)correspond to that of the product obtained in the Example 1.
Reference: [1] Patent: WO2017/39425, 2017, A1, . Location in patent: Page/Page column 6; 7
  • 6
  • [ 101-55-3 ]
  • [ 1276110-38-3 ]
  • [ 1022150-11-3 ]
YieldReaction ConditionsOperation in experiment
70%
Stage #1: With palladium dichloro <1,1'-bis(diphenylphosphino)ferrocene>; potassium acetate In 1,4-dioxane at 100℃; for 5 h;
Stage #2: at 100℃; for 22 h;
4-Bromodiphenyl ether (X = Br) (3.74 g, 15 mmol) was dissolved in 1,4-dioxane (50 ml)Addition of pinacol diboronate(4.52 g, 18 mmol),Potassium acetate (1.78 g, 18 mmol).Then, the catalyst [1,1'-bis (diphenylPhosphine) ferrocene] palladium dichloride [Pd (dppf) 2Cl2] (1.5 mmol, 1.11 g).With stirring, heated to 100 ° C, the reaction 5h (TLCDetection of raw materials disappear).Then, Intermediate (14) (4.44 g, 10 mmol) was added, and the reaction was maintained at 100 ° C for 22 hours14 disappears).Then, after distilling off the organic solvent, Intermediate (9) (yellow solid, 3.41 g, yield 70percent, chemical purity and optical purity> = 99percent) was obtained.
Reference: [1] Patent: CN104557945, 2017, B, . Location in patent: Paragraph 0055-0057; 0059-0062; 0063-0068
  • 7
  • [ 330786-24-8 ]
  • [ 1353993-49-3 ]
  • [ 1022150-11-3 ]
YieldReaction ConditionsOperation in experiment
77 g With caesium carbonate In 1-methyl-pyrrolidin-2-one at 70 - 75℃; for 12 h; Inert atmosphere A mixture of 3 -(4-phenoxyphenyl)- 1 H-pyra.zolo [3 ,4-d]pyrimidin-4-amine compoundof formula-9 (60 gms), NMP (480 ml), (S)-tert-butyl-3-(tosyloxy)piperidine- 1 -carboxylatecompound of formula-ha (86 gms) and cesium carbonate (161 gms) was heated to 70-75°C under nitrogen atmosphere and stirred for 12 hrs. Cooled the reaction mixture to 25-30°C. Ethyl acetate was added to the reaction mixture at 25-30°C. Filtered the reaction mixture and washed with ethyl acetate. Water was added to the filtrate at 25-30°C and stirred for 15 mins.Both the organic and aqueous layers were separated. The organic layer was washed with water. Distilled off the solvent from the organic layer completely under reduced pressure to get the title compound. Yield: 77 gms.
Reference: [1] Patent: WO2016/170545, 2016, A1, . Location in patent: Page/Page column 33
  • 8
  • [ 1419223-01-0 ]
  • [ 51067-38-0 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: WO2016/151438, 2016, A1, . Location in patent: Page/Page column 13-14
  • 9
  • [ 330786-24-8 ]
  • [ 143900-43-0 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: CN106188062, 2016, A, . Location in patent: Paragraph 0078; 0079; 0080; 0081
  • 10
  • [ 1612774-50-1 ]
  • [ 3473-63-0 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: WO2014/139970, 2014, A1, . Location in patent: Page/Page column 19; 25
  • 11
  • [ 151266-23-8 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: WO2012/158795, 2012, A1,
[2] Patent: WO2013/191965, 2013, A1,
[3] Patent: WO2013/191965, 2013, A1,
[4] Patent: WO2014/22569, 2014, A1,
[5] Patent: WO2014/22569, 2014, A1,
[6] Patent: WO2014/22390, 2014, A1,
[7] Patent: US8673925, 2014, B1,
[8] Patent: US8673925, 2014, B1,
[9] Organic and Biomolecular Chemistry, 2015, vol. 13, # 18, p. 5147 - 5157
[10] Journal of Medicinal Chemistry, 2015, vol. 58, # 24, p. 9625 - 9638
[11] Patent: WO2016/151438, 2016, A1,
[12] Patent: CN105399756, 2016, A,
[13] Patent: CN106146511, 2016, A,
[14] Patent: CN104557945, 2017, B,
[15] Patent: CN107759602, 2018, A,
  • 12
  • [ 2380-63-4 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: WO2012/158795, 2012, A1,
[2] Patent: WO2013/191965, 2013, A1,
[3] Patent: WO2013/191965, 2013, A1,
[4] Patent: WO2014/22569, 2014, A1,
[5] Patent: WO2014/22569, 2014, A1,
[6] Patent: WO2014/22390, 2014, A1,
[7] Patent: US8673925, 2014, B1,
[8] Patent: US8673925, 2014, B1,
[9] Organic and Biomolecular Chemistry, 2015, vol. 13, # 18, p. 5147 - 5157
[10] Journal of Medicinal Chemistry, 2015, vol. 58, # 24, p. 9625 - 9638
[11] Patent: WO2016/151438, 2016, A1,
[12] Patent: WO2016/151438, 2016, A1,
[13] Patent: CN105399756, 2016, A,
[14] Patent: CN104557945, 2017, B,
[15] Patent: CN107759602, 2018, A,
  • 13
  • [ 143900-44-1 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: WO2013/191965, 2013, A1,
[2] Patent: WO2014/22569, 2014, A1,
[3] Patent: US8673925, 2014, B1,
[4] Patent: WO2016/170545, 2016, A1,
[5] Patent: WO2016/151438, 2016, A1,
[6] Patent: WO2016/151438, 2016, A1,
[7] Patent: CN105399756, 2016, A,
[8] Patent: CN106146511, 2016, A,
[9] Patent: WO2017/137446, 2017, A1,
  • 14
  • [ 2215-77-2 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: WO2016/170545, 2016, A1,
[2] Patent: CN106188062, 2016, A,
[3] Patent: WO2017/137446, 2017, A1,
[4] Patent: WO2017/163257, 2017, A1,
  • 15
  • [ 1353993-49-3 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: WO2013/191965, 2013, A1,
[2] Patent: WO2014/22569, 2014, A1,
[3] Patent: US8673925, 2014, B1,
  • 16
  • [ 101-55-3 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: CN105622613, 2016, A,
[2] Patent: CN106146511, 2016, A,
[3] Patent: CN107759602, 2018, A,
  • 17
  • [ 330792-69-3 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: WO2016/170545, 2016, A1,
[2] Patent: WO2017/137446, 2017, A1,
[3] Patent: WO2017/163257, 2017, A1,
  • 18
  • [ 1623-95-6 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: CN106188062, 2016, A,
[2] Patent: WO2017/137446, 2017, A1,
[3] Patent: WO2017/163257, 2017, A1,
  • 19
  • [ 330792-70-6 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: CN106188062, 2016, A,
[2] Patent: WO2017/163257, 2017, A1,
  • 20
  • [ 940890-90-4 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: WO2016/151438, 2016, A1,
[2] Patent: WO2016/151438, 2016, A1,
  • 21
  • [ 5305-40-8 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: CN105622613, 2016, A,
  • 22
  • [ 108-95-2 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: WO2016/170545, 2016, A1,
  • 23
  • [ 459-57-4 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: WO2016/170545, 2016, A1,
  • 24
  • [ 83255-86-1 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: WO2016/151438, 2016, A1,
  • 25
  • [ 24424-99-5 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: WO2017/137446, 2017, A1,
  • 26
  • [ 269410-26-6 ]
  • [ 1022150-11-3 ]
Reference: [1] Patent: CN107759602, 2018, A,
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 1022150-11-3 ]

Ibrutinib Related Intermediates

Chemical Structure| 51067-38-0

[ 51067-38-0 ]

(4-Phenoxyphenyl)boronic acid

Chemical Structure| 2215-77-2

[ 2215-77-2 ]

4-Phenoxybenzoic acid

Chemical Structure| 2380-63-4

[ 2380-63-4 ]

1H-Pyrazolo[3,4-d]pyrimidin-4-amine

Chemical Structure| 330786-24-8

[ 330786-24-8 ]

3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Chemical Structure| 151266-23-8

[ 151266-23-8 ]

3-Iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Related Functional Groups of
[ 1022150-11-3 ]

Aryls

Chemical Structure| 330786-24-8

[ 330786-24-8 ]

3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Similarity: 0.74

Chemical Structure| 1188296-52-7

[ 1188296-52-7 ]

3-((3-Chlorophenoxy)methyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Similarity: 0.69

Chemical Structure| 1665288-67-4

[ 1665288-67-4 ]

Benzyl 2,4-dichloro-6,7-dihydropyrido[2,3-d]pyrimidine-8(5H)-carboxylate

Similarity: 0.58

Chemical Structure| 139756-21-1

[ 139756-21-1 ]

5-(2-Ethoxyphenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one

Similarity: 0.58

Chemical Structure| 883984-95-0

[ 883984-95-0 ]

Benzyl 7'-chloro-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-d][1,3]oxazine]-1-carboxylate

Similarity: 0.57

Ethers

Chemical Structure| 330786-24-8

[ 330786-24-8 ]

3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Similarity: 0.74

Chemical Structure| 1188296-52-7

[ 1188296-52-7 ]

3-((3-Chlorophenoxy)methyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Similarity: 0.69

Chemical Structure| 139756-21-1

[ 139756-21-1 ]

5-(2-Ethoxyphenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one

Similarity: 0.58

Chemical Structure| 877399-51-4

[ 877399-51-4 ]

(R)-tert-Butyl 4-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate

Similarity: 0.57

Chemical Structure| 1377049-84-7

[ 1377049-84-7 ]

Methyl ((2S)-1-((2S,5S)-2-(9-(2-((2S,4S)-1-((2R)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-4-(methoxymethyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate

Similarity: 0.55

Amides

Chemical Structure| 1616415-40-7

[ 1616415-40-7 ]

(S)-tert-Butyl 4-(6-amino-1,3-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate

Similarity: 0.78

Chemical Structure| 916258-24-7

[ 916258-24-7 ]

tert-Butyl 5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine-1-carboxylate

Similarity: 0.64

Chemical Structure| 866084-31-3

[ 866084-31-3 ]

tert-Butyl 4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate

Similarity: 0.63

Chemical Structure| 205264-33-1

[ 205264-33-1 ]

1-Boc-4-Isoquinolin-1-yl-piperazine

Similarity: 0.60

Chemical Structure| 571188-82-4

[ 571188-82-4 ]

tert-Butyl 4-(6-((6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate

Similarity: 0.60

Amines

Chemical Structure| 1616415-40-7

[ 1616415-40-7 ]

(S)-tert-Butyl 4-(6-amino-1,3-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate

Similarity: 0.78

Chemical Structure| 330786-24-8

[ 330786-24-8 ]

3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Similarity: 0.74

Chemical Structure| 1188296-52-7

[ 1188296-52-7 ]

3-((3-Chlorophenoxy)methyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Similarity: 0.69

Chemical Structure| 866084-31-3

[ 866084-31-3 ]

tert-Butyl 4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate

Similarity: 0.63

Chemical Structure| 571188-82-4

[ 571188-82-4 ]

tert-Butyl 4-(6-((6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate

Similarity: 0.60

Related Parent Nucleus of
[ 1022150-11-3 ]

Other Aromatic Heterocycles

Chemical Structure| 1616415-40-7

[ 1616415-40-7 ]

(S)-tert-Butyl 4-(6-amino-1,3-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate

Similarity: 0.78

Chemical Structure| 330786-24-8

[ 330786-24-8 ]

3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Similarity: 0.74

Chemical Structure| 1188296-52-7

[ 1188296-52-7 ]

3-((3-Chlorophenoxy)methyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Similarity: 0.69

Chemical Structure| 916258-24-7

[ 916258-24-7 ]

tert-Butyl 5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine-1-carboxylate

Similarity: 0.64

Chemical Structure| 866084-31-3

[ 866084-31-3 ]

tert-Butyl 4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate

Similarity: 0.63

Piperidines

Chemical Structure| 889945-69-1

[ 889945-69-1 ]

tert-Butyl 4-(1H-indazol-3-yl)piperidine-1-carboxylate

Similarity: 0.57

Chemical Structure| 883984-95-0

[ 883984-95-0 ]

Benzyl 7'-chloro-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-d][1,3]oxazine]-1-carboxylate

Similarity: 0.57

Chemical Structure| 877399-51-4

[ 877399-51-4 ]

(R)-tert-Butyl 4-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate

Similarity: 0.57

Chemical Structure| 1038866-44-2

[ 1038866-44-2 ]

Spiro[piperidine-4,4'-pyrido[2,3-d][1,3]oxazin]-2'(1'H)-one hydrochloride

Similarity: 0.56

Chemical Structure| 1198408-35-3

[ 1198408-35-3 ]

tert-Butyl 4-(6-aminopyridin-3-yl)piperidine-1-carboxylate

Similarity: 0.53